{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T10:56:38Z","timestamp":1772794598739,"version":"3.50.1"},"reference-count":91,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T00:00:00Z","timestamp":1086652800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2005,1]]},"DOI":"10.1007\/s00262-004-0549-1","type":"journal-article","created":{"date-parts":[[2004,6,8]],"date-time":"2004-06-08T03:07:59Z","timestamp":1086664079000},"page":"1-10","source":"Crossref","is-referenced-by-count":70,"title":["New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-?) treatment of human cancer"],"prefix":"10.1007","volume":"54","author":[{"given":"Pierosandro","family":"Tagliaferri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfredo","family":"Budillon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Vitale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caterina","family":"Viscomi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Masciari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierfrancesco","family":"Tassone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Venuta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2004,6,8]]},"reference":[{"key":"CR2","doi-asserted-by":"crossref","first-page":"29991","DOI":"10.1074\/jbc.272.48.29991","volume":"272","author":"Ahmad","year":"1997","unstructured":"Ahmad S, Alsayed Y, Druker BJ, Platanias LC (1997) The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J Biol Chem 272:29991?29994","journal-title":"J Biol Chem"},{"key":"CR1","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/S0140-6736(95)92596-1","volume":"345","author":"Allan","year":"1995","unstructured":"Allan NC, Richards SM, Shepherd PC (1995) UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council?s working parties for therapeutic trials in adult leukaemia. Lancet 345:1392?1397","journal-title":"Lancet"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/cncr.10783","volume":"95","author":"Atzpodien","year":"2002","unstructured":"Atzpodien J, Hoffmann R, Franzke M, Stief C, Wandert T, Reitz M (2002) Thirteen-year, long-term efficacy of interferon 2-alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma. Cancer 95:1045?1050","journal-title":"Cancer"},{"key":"CR4","first-page":"1671","volume":"5","author":"Berg","year":"1999","unstructured":"Berg WJ, Nanus DM, Leung A, Brown KT, Hutchinson B, Mazumdar M, Xu XC, Lotan R, Reuter VE, Motzer RJ (1999) Up-regulation of retinoic acid receptor beta expression in renal cancers in vivo correlates with response to 13-cis-retinoic acid and interferon-alpha-2a. Clin Cancer Res 5:1671?1675","journal-title":"Clin Cancer Res"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1074-7613(01)00154-6","volume":"14","author":"Biron","year":"2001","unstructured":"Biron CA (2001) Interferons alpha and beta as immune regulators?a new look. Immunity 14:661?664","journal-title":"Immunity"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/S0092-8674(00)80595-4","volume":"96","author":"Brunet","year":"1999","unstructured":"Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME (1999) Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96:857?868","journal-title":"Cell"},{"key":"CR7","first-page":"1294","volume":"51","author":"Budillon","year":"1991","unstructured":"Budillon A, Tagliaferri P, Caraglia M, Torrisi MR, Normanno N, Iacobelli S, Palmieri G, Stoppelli MP, Frati L, Bianco AR (1991) Upregulation of epidermal growth factor receptor induced by alpha-interferon in human epidermoid cancer cells. Cancer Res 51:1294?1299","journal-title":"Cancer Res"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1172\/JCI119814","volume":"100","author":"Buechner","year":"1997","unstructured":"Buechner S, Wernli M, Hass T, Hahn S, Itin P, Erb P (1997) Regression of basal carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1\/Fas)-CD95 ligand-induced suicide. J Clin Invest 100:2691?2696","journal-title":"J Clin Invest"},{"key":"CR9","doi-asserted-by":"crossref","first-page":"3841","DOI":"10.1200\/JCO.2002.02.051","volume":"20","author":"Bukowski","year":"2002","unstructured":"Bukowski R, Ernstoff MS, Gore ME, Nemunaitis JJ, Amato R, Gupta SK, Tendler CL (2002) Pegylated interferon alfa-2b treatment for patients with solid tumours: a phase I\/II study. J Clin Oncol 20:3841?3849","journal-title":"J Clin Oncol"},{"key":"CR10","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1002\/cncr.10663","volume":"95","author":"Bukowski","year":"2002","unstructured":"Bukowski RM, Tendler C, Cutler D, Rose E, Laughlin MM, Statkevich P (2002) Treating cancer with PEG intron: pharmacokinetic profile and dosing guidelines for an improved interferon-alpha-2b formulation. Cancer 95:389?396","journal-title":"Cancer"},{"key":"CR11","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1002\/ijc.2910610312","volume":"61","author":"Caraglia","year":"1995","unstructured":"Caraglia M, Leardi A, Corradino S, Ciardiello F, Budillon A, Guarrasi R, Bianco AR, Tagliaferri P (1995) Alpha-interferon potentiates epidermal growth factor receptor-mediated effects on human epidermoid carcinoma KB cells. Int J Cancer 61:342?347","journal-title":"Int J Cancer"},{"key":"CR12","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.cdd.4400550","volume":"Differ","author":"Caraglia","year":"1999","unstructured":"Caraglia M, Abbruzzese A, Leardi A, Pepe S, Budillon A, Baldassare G, Selleri C, Lorenzo SD, Fabbrocini A, Giuberti G, Vitale G, Lupoli G, Bianco AR, Tagliaferri P (1999) Interferon-alpha induces apoptosis in human KB cells through a stress-dependent mitogen activated protein kinase pathway that is antagonized by epidermal growth factor. Cell Death Differ 6:773?780","journal-title":"Cell Death"},{"key":"CR13","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/sj.cdd.4401131","volume":"10","author":"Caraglia","year":"2003","unstructured":"Caraglia M, Tagliaferri P, Marra M, Giuberti G, Budillon A, Gennaro ED, Pepe S, Vitale G, Improta S, Tassone P, Venuta S, Bianco AR, Abbruzzese A (2003) EGF activates an inducible survival response via the Ras?ERK-1\/2 pathway to counteract interferon-alpha-mediated apoptosis in epidermoid cancer cells. Cell Death Differ 10:218?229","journal-title":"Cell Death Differ"},{"key":"CR14","doi-asserted-by":"crossref","unstructured":"Caraglia M, Marra M, Giuberti G, D?Alessandro AM, Baldi A, Tassone P, Venuta S, Tagliaferri P, Abbruzzese A (2003) The eukaryotic initiation factor 5A is involved in the regulation of proliferation and apoptosis induced by interferon-alpha and EGF in human cancer cells. J Biochem (Tokyo) 133:757","DOI":"10.1093\/jb\/mvg097"},{"key":"CR15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","volume":"282","author":"Cardone","year":"1998","unstructured":"Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318?1321","journal-title":"Science"},{"key":"CR16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1038\/sj.leu.2402824","volume":"17","author":"Chang","year":"2003","unstructured":"Chang F, Lee JT, Navolanic PM, Steelman LS, Shelton JG, Blalock WL, Franklin RA, McCubrey JA (2003) Involvement of PI3 K\/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590?603","journal-title":"Leukemia"},{"key":"CR17","first-page":"1821","volume":"7","author":"Chawla-Sarkar","year":"2001","unstructured":"Chawla-Sarkar M, Leaman DW, Borden EC (2001) Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-alpha2: correlation with TRAIL\/Apo2L induction in melanoma cell lines. Clin Cancer Res 7:1821?1831","journal-title":"Clin Cancer Res"},{"key":"CR18","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1023\/A:1023668705040","volume":"8","author":"Chawla-Sarkar","year":"2003","unstructured":"Chawla-Sarkar M, Lindner DJ, Liu YF, Williams BR, Sen GC, Silverman RH, Borden EC (2003) Apoptosis and interferons: role of interferon-stimulated genes as mediators of apoptosis. Apoptosis 8:237?249","journal-title":"Apoptosis"},{"key":"CR21","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1128\/MCB.15.8.4208","volume":"15","author":"Cohen","year":"1995","unstructured":"Cohen B, Novick D, Barak S, Rubinstein M (1995) Ligand-induced association of the type I interferon receptor components. Mol Cell Biol 15:4208?4214","journal-title":"Mol Cell Biol"},{"key":"CR22","doi-asserted-by":"crossref","first-page":"8133","DOI":"10.1128\/MCB.14.12.8133","volume":"14","author":"Colamonici","year":"1994","unstructured":"Colamonici O, Yan H, Domanski P, Handa R, Smalley D, Mullersman J, Witte M, Krishnan K, Krolewski J (1994) Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol Cell Biol 14:8133?8142","journal-title":"Mol Cell Biol"},{"key":"CR23","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/sj.cdd.4401281","volume":"10","author":"Costelli","year":"2003","unstructured":"Costelli P, Aoki P, Zingaro B, Carbo N, Reffo P, Lopez-Soriano FJ, Bonelli G, Argiles JM, Baccino FM (2003) Mice lacking TNFalpha receptors 1 and 2 are resistant to death and fulminant liver injury induced by agonistic anti-Fas antibody. Cell Death Differ 10:997?1004","journal-title":"Cell Death Differ"},{"key":"CR24","first-page":"33165","volume":"271","author":"Croze","year":"1996","unstructured":"Croze E, Russell-Harde D, Wagner TC, Pu H, Pfeffer LM, Perez HD (1996) Reconstitution of a high affinity binding site for type I interferons. J Biol Chem 271:33165?33168","journal-title":"Reconstitution of a high affinity binding site for type I interferons J Biol Chem"},{"key":"CR25","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1126\/science.8197455","volume":"264","author":"Darnell","year":"1994","unstructured":"Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415?1421","journal-title":"Science"},{"key":"CR26","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0092-8674(00)80405-5","volume":"91","author":"Datta","year":"1997","unstructured":"Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME (1997) Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell Oct 91:231?241","journal-title":"Cell Oct"},{"key":"CR27","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.1074\/jbc.271.9.4585","volume":"271","author":"David","year":"1996","unstructured":"David M, Petricoin E III, Larner AC (1996) Activation of protein Kinase A inhibits interferon induction of the Jak\/Stat pathway in U266 cells. J Biol Chem 271:4585?4588","journal-title":"J Biol Chem"},{"key":"CR28","doi-asserted-by":"crossref","first-page":"9138","DOI":"10.1128\/MCB.20.24.9138-9148.2000","volume":"20","author":"Dijkers","year":"2000","unstructured":"Dijkers PF, Medema RH, Pals C, Banerji L, Thomas NS, Lam EW, Burgering BM, Raaijmakers JA, Lammers JW, Koenderman L, Coffer PJ (2000) Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 20:9138?9148","journal-title":"Mol Cell Biol"},{"key":"CR29","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0960-9822(00)00728-4","volume":"10","author":"Dijkers","year":"2000","unstructured":"Dijkers PF, Medema RH, Lammers JW, Koenderman L, Coffer PJ (2000) Expression of the pro-apoptotic Bcl-2 family member Bim is regulated by the forkhead transcription factor FKHR-L1. Curr Biol 10:1201?1204","journal-title":"Curr Biol"},{"key":"CR30","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1083\/jcb.200108084","volume":"156","author":"Dijkers","year":"2002","unstructured":"Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L, Coffer PJ (2002) FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 156:531?542","journal-title":"J Cell Biol"},{"key":"CR31","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199205283262203","volume":"326","author":"Ezekowitz","year":"1992","unstructured":"Ezekowitz RA, Mulliken JB, Folkman J (1992) Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med 326:1456?1463","journal-title":"N Engl J Med"},{"key":"CR32","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1023\/A:1026548226770","volume":"11","author":"Fritz","year":"2000","unstructured":"Fritz E, Ludwin H (2000) Interferon alpha treatment in multiple myeloma: meta-analysis of 30 randomized trials among 3948 patients. Ann Oncol 11:1427?1436","journal-title":"Ann Oncol"},{"key":"CR84","doi-asserted-by":"crossref","first-page":"8555","DOI":"10.1073\/pnas.87.21.8555","volume":"87","author":"X","year":"1990","unstructured":"Fu X, Kessler DS, Veals SA, Levy DE, Darnell JE (1990) The transcriptional activator induced by interferon ?, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci U S A 87:8555?8559","journal-title":"Proc Natl Acad Sci U S A"},{"key":"CR33","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1023\/A:1009664109241","volume":"5","author":"Gil","year":"2000","unstructured":"Gil J, Esteban M (2000) Induction of apoptosis by the dsRNA-dependent protein kinase (PKR): mechanism of action. Apoptosis 5:107?114","journal-title":"Apoptosis"},{"key":"CR34","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood.V97.9.2791","volume":"97","author":"Gisslinger","year":"2001","unstructured":"Gisslinger H, Kurzrock R, Gisslinger B, Jiang S, Li S, Virgolini I, Woloszczuk W, Andreeff M, Talpaz M (2001) Autocrine cell suicide in a Burkitt lymphoma cell line (Daudi) induced by interferon alpha: involvement of tumour necrosis factor as ligand for the CD95 receptor. Blood 97:2791?2797","journal-title":"Blood"},{"key":"CR35","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1177\/107327480200900103","volume":"9","author":"Gray","year":"2002","unstructured":"Gray RJ, Pockaj BA, Kirkwood JM (2002) An update on adjuvant interferon for melanoma. Cancer Control 9:16?21","journal-title":"Cancer Control"},{"key":"CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1053\/sonc.2002.33079","volume":"29","author":"Herberman","year":"2002","unstructured":"Herberman RB (2002) Cancer immunotherapy with natural killer cells. Semin Oncol 29(Suppl 7):27?30","journal-title":"Semin Oncol"},{"key":"CR73","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1056\/NEJM199403243301204","volume":"330","author":"The","year":"1994","unstructured":"Italian Cooperative Study Group on chronic myeloid leukemia (1994) Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820?825","journal-title":"N Engl J Med"},{"key":"CR37","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1357-2725(98)00136-8","volume":"31","author":"Jagus","year":"1999","unstructured":"Jagus R, Joshi B, Barber GN (1999) PKR, apoptosis and cancer. Int J Biochem Cell Biol 31:123?138","journal-title":"Int J Biochem Cell Biol"},{"key":"CR38","first-page":"review","volume":"practice","author":"Jonasch","year":"2001","unstructured":"Jonasch E, Haluska FG (2001) Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 34?55","journal-title":"Interferon in oncological"},{"key":"CR39","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1517\/phgs.4.3.245.22696","volume":"4","author":"Khan","year":"2003","unstructured":"Khan J (2003) Genomic and Proteomic technological advances in cancer research. Pharmacogenomics 4:245?249","journal-title":"Pharmacogenomics"},{"key":"CR40","doi-asserted-by":"crossref","first-page":"8741","DOI":"10.1038\/sj.onc.1205987","volume":"21","author":"Kim","year":"2002","unstructured":"Kim SH, Gunnery S, Choe JK, Mathews MB (2002) Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21:8741?8748","journal-title":"Oncogene"},{"key":"CR41","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1200\/JCO.1996.14.1.7","volume":"14","author":"Kirkwood","year":"1996","unstructured":"Kirkwood JM, Strawderman MH, Ernstoff MS, Smith TJ, Borden EC, Blum RH (1996) Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma in the Eastern Cooperative Oncology Group trial EST 1684. J Clin Oncol 14:7?17","journal-title":"J Clin Oncol"},{"key":"CR42","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2000.18.12.2444","volume":"18","author":"Kirkwood","year":"2000","unstructured":"Kirkwood JM, Ibrahim JG, Sondak VK, Richards J, Flaherty LE, Ernstoff MS, Smith TJ, Rao U, Steele M, Blum RH (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690\/S9111\/C9190. J Clin Oncol 18:2444?2458","journal-title":"J Clin Oncol"},{"key":"CR43","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1200\/JCO.2001.19.5.1430","volume":"19","author":"Kirkwood","year":"2001","unstructured":"Kirkwood JM, Ibrahim J, Lawson DH, Atkins MB, Agarwala SS, Collins K, Mascari R, Morrissey DM, Chapman PB (2001) High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696. J Clin Oncol 19:1430?1436","journal-title":"J Clin Oncol"},{"key":"CR44","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1002\/cncr.10775","volume":"95","author":"Kirkwood","year":"2002","unstructured":"Kirkwood JM, Richards T, Zarour HM, Sosman J, Ernstoff M, Whiteside TL, Ibrahim J, Blum R, Wieand S, Mascari R (2002) Immunomodulatory effects of high-dose and low-dose interferon alpha2b in patients with high-risk resected melanoma: the E2690 laboratory corollary of intergroup adjuvant trial E1690. Cancer 95:1101?1112","journal-title":"Cancer"},{"key":"CR45","doi-asserted-by":"crossref","first-page":"46278","DOI":"10.1074\/jbc.M304721200","volume":"278","author":"Klampfer","year":"2003","unstructured":"Klampfer L, Huang J, Corner G, Mariadason J, Arango D, Sasazuki T, Shirasawa S, Augenlicht L (2003) Oncogenic k-ras inhibits the expression of IFN-responsive genes through inhibition of STAT1 and STAT2 expression. J Biol Chem 278:46278?46287","journal-title":"J Biol Chem"},{"key":"CR46","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1126\/science.1708916","volume":"252","author":"Koch","year":"1991","unstructured":"Koch CA, Anderson D, Moran MF, Ellis C, Pawson T (1991) SH2 and SH3 domains: elements that control interactions of cytoplasmic signalling proteins. Science 252:668?674","journal-title":"Science"},{"key":"CR47","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1002\/bies.10329","volume":"25","author":"Lawen","year":"2003","unstructured":"Lawen A (2003) Apoptosis-an introduction. Bioessays 25:888?896","journal-title":"Bioessays"},{"key":"CR48","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1172\/JCI16603","volume":"112","author":"Lesinski","year":"2003","unstructured":"Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, Hu Y, Becknell B, Abood G, Chaudhury AR, Magro C, Durbin J, Carson WE III (2003) The antitumour effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest 112:170?180","journal-title":"J Clin Invest"},{"key":"CR49","doi-asserted-by":"crossref","first-page":"4362","DOI":"10.1093\/emboj\/19.16.4362","volume":"19","author":"Lipowsky","year":"2000","unstructured":"Lipowsky G, Bischoff FR, Schwarzmaier P, Kraft R, Kostka S, Hartmann E, Kutay U, Gorlich D (2000) Exportin 4: a mediator of a novel nuclear export pathway in higher eukaryotes. EMBO J 19:4362?4371","journal-title":"EMBO J"},{"key":"CR50","doi-asserted-by":"crossref","first-page":"10626","DOI":"10.1073\/pnas.95.18.10626","volume":"95","author":"Liu","year":"1998","unstructured":"Liu B, Liao J, Rao X, Kushner SA, Chung CD, Chang DD, Shuai K (1998) Inhibition of Stat1-mediated gene activation by PIAS1. Proc Natl Acad Sci U S A 95:10626?10631","journal-title":"Proc Natl Acad Sci U S A"},{"key":"CR51","doi-asserted-by":"crossref","first-page":"5100","DOI":"10.1002\/j.1460-2075.1995.tb00192.x","volume":"14","author":"Lutfalla","year":"1995","unstructured":"Lutfalla G, Holland SJ, Cinato E, Monneron D, Reboul J, Rogers NC, Smith JM, Stark GR, Gardiner K, Morgensen KE, Kerr IM, Uz\u00e9 G (1995) Mutant U5A cells are complemented by an interferon-alpha beta receptor subunit generated by alternative processing of a new member of a cytokine receptor gene cluster. EMBO J 14:5100?5108","journal-title":"EMBO J"},{"key":"CR52","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1634\/theoncologist.4-4-332","volume":"4","author":"Lyonel","year":"1999","unstructured":"Israel LG, Israel ED (1999) Apoptosis. The Oncologist 4:332?339","journal-title":"The Oncologist"},{"key":"CR53","doi-asserted-by":"crossref","first-page":"28570","DOI":"10.1074\/jbc.M011685200","volume":"276","author":"Mayer","year":"2001","unstructured":"Mayer IA, Verma A, Grumbach IM, Uddin S, Lekmine F, Ravandi F, Majchrzak B, Fujita S, Fish EN, Platanias LC (2001) The p38 MAPK pathway mediates the growth inhibitory effects of interferon-alpha in BCR-ABL-expressing cells. J Biol Chem 276:28570?28577","journal-title":"J Biol Chem"},{"key":"CR54","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0140-6736(98)03544-2","volume":"353","author":"Medical","year":"1999","unstructured":"Medical Research Council Renal Cancer Collaborators (1999) Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 353:14?17","journal-title":"Lancet"},{"key":"CR55","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1677\/joe.0.1780205","volume":"178","author":"Mitsiades","year":"2003","unstructured":"Mitsiades CS, Poulaki V, Mitsiades N (2003) The role of apoptosis-inducing receptors of the tumour necrosis factor family in thyroid cancer. J Endocrinol 178:205?216","journal-title":"J Endocrinol"},{"key":"CR56","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1200\/JCO.1995.13.8.1950","volume":"13","author":"Motzer","year":"1995","unstructured":"Motzer RJ, Schwartz L, Law TM, Murphy BA, Hoffman AD, Albino AP, Vlamis V, Nanus DM (1995) Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumour activity in a phase II trial and interactions in vitro. J Clin Oncol 13:1950?1957","journal-title":"J Clin Oncol"},{"key":"CR57","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1200\/JCO.2001.19.5.1312","volume":"19","author":"Motzer","year":"2001","unstructured":"Motzer RJ, Rakhit A, Ginsberg M, Rittweger K, Vuky J, Yu R, Fettner S, Hooftman L (2001) Phase I trial of 40-kd branched pegylated interferon alfa-2a for patients with advanced renal cell carcinoma. J Clin Oncol 19:1312?1319","journal-title":"J Clin Oncol"},{"key":"CR74","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1046\/j.1365-2141.2001.02857.x","volume":"113","author":"The","year":"2001","unstructured":"Myeloma Trialists? Collaborative Group (2001) Interferon as therapy for multiple myeloma: an individual patient data overview of 24 randomized trials and 4012 patients. Br J Haematol 113:1020?1034","journal-title":"Br J Haematol"},{"key":"CR58","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1074\/jbc.274.7.4045","volume":"274","author":"Nadeau","year":"1999","unstructured":"Nadeau O, Domanski P, Usacheva A, Uddin S, Platanias LC, Pitha P, Raz R, Levy D, Majchrzak B, Fish E, Colamonici OR (1999) A Region of the subunit of the interferon receptor different from box 1 interacts with Jak1 and is sufficient to activate the Jak?Stat pathway and induce an antiviral state. J Biol Chem 274:4045?4052","journal-title":"J Biol Chem"},{"key":"CR59","first-page":"150","volume":"9","author":"Navarro","year":"1996","unstructured":"Navarro S, Colamonici OR, Llombart-Bosch A (1996) Immunohistochemical detection of the type I interferon receptor in human fetal, adult, and neoplastic tissues. Mod Pathol 9:150?156","journal-title":"Mod Pathol"},{"key":"CR60","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/0092-8674(94)90154-6","volume":"77","author":"Novick","year":"1994","unstructured":"Novick D, Cohen B, Rubinstein M (1994) The human interferon alpha\/beta receptor-Characterization and molecular cloning. Cell 77:391?400","journal-title":"Cell"},{"key":"CR61","doi-asserted-by":"crossref","first-page":"4011","DOI":"10.1046\/j.1432-1327.2000.01433.x","volume":"267","author":"Nyman","year":"2000","unstructured":"Nyman TA, Matikainen S, Sareneva T, Julkunen I, Kalkkinen N (2000) Proteome analysis reveals ubiquitin-conjugating enzymes to be a new family of interferon-alpha-regulated genes. Eur J Biochem 267:4011?4011","journal-title":"Eur J Biochem"},{"key":"CR62","first-page":"S9","volume":"24","author":"Pestka","year":"1997","unstructured":"Pestka S (1997) The human interferon-alpha species and hybrid proteins. Semin Oncol 24:S9-4?S9-17","journal-title":"Semin Oncol"},{"key":"CR63","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.1200\/JCO.1999.17.9.2859","volume":"17","author":"Pyrhonen","year":"1999","unstructured":"Pyrhonen S, Salminen E, Ruutu M, Lehtonen T, Nurmi M, Tammela T, Juusela H, Rintala E, Hietanen P, Kellokumpu-Lehtinen PL (1999) Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 17:2859?2867","journal-title":"J Clin Oncol"},{"key":"CR64","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ijc.2910610119","volume":"61","author":"Rodriguez-Villanueva","year":"1995","unstructured":"Rodriguez-Villanueva J, McDonnell TJ (1995) Induction of apoptotic cell death in non-melanoma skin cancer by interferon-alpha. Int J Cancer 61:110?114","journal-title":"Int J Cancer"},{"key":"CR65","first-page":"951","volume":"86","author":"Sacchi","year":"2001","unstructured":"Sacchi S, Federico M, Vitolo U, Boccomini C, Vallisa D, Baldini L, Petrini M, Rupoli S, Di Raimondo F, Merli F, Liso V, Tabilio A, Saglio G, Vinci G, Brugiatelli M, Dastoli G, Gis L (2001) Clinical activity and safety of combination immunotherapy with IFN-alpha 2a and rituximab in patients with relapsed low grade non-Hodgkin?s lymphoma. Haematologica 86:951?958","journal-title":"Haematologica"},{"key":"CR66","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1038\/sj.onc.1202609","volume":"18","author":"Sangfelt","year":"1999","unstructured":"Sangfelt O, Erickson S, Castro J, Heiden T, Gustafsson A, Einhorn S, Grander D (1999) Molecular mechanisms underlying interferon-alpha-induced G0\/G1 arrest: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins. Oncogene 18:2798?2810","journal-title":"Oncogene"},{"key":"CR67","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1146\/annurev.bi.64.070195.003201","volume":"64","author":"Schindler","year":"1995","unstructured":"Schindler C, Darnell JE (1995) Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 64:621?651","journal-title":"Annu Rev Biochem"},{"key":"CR68","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1182\/blood.V89.3.957","volume":"89","author":"Selleri","year":"1997","unstructured":"Selleri C, Sato T, Del Vecchio L, Luciano L, Barrett AJ, Rotoli B, Neal S Young, Maciejewski JP (1997) Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-? in chronic myelogenous leukemia. Blood 89:957?964","journal-title":"Blood"},{"key":"CR69","first-page":"2726","volume":"5","author":"Slaton","year":"1999","unstructured":"Slaton JW, Perrotte P, Inoue K, Dinney CP, Fidler IJ (1999) Interferon-alpha-mediated down-regulation of angiogenesis-related genes and therapy of bladder cancer are dependent on optimization of biological dose and schedule. Clin Cancer Res 5:2726?2734","journal-title":"Clin Cancer Res"},{"key":"CR70","doi-asserted-by":"crossref","first-page":"35056","DOI":"10.1074\/jbc.273.52.35056","volume":"273","author":"Song","year":"1998","unstructured":"Song MM, Shuai K (1998) The suppressor of cytokine signaling (SOCS) 1 and SOCS3 but not SOCS2 proteins inhibit interferon-mediated antiviral and antiproliferative activities. J Biol Chem 273:35056?35062","journal-title":"J Biol Chem"},{"key":"CR71","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1126\/science.7871433","volume":"267","author":"Stahl","year":"1995","unstructured":"Stahl N, Farruggella TJ, Boulton TG, Zhong Z, Darnell JE Jr, Yancopoulos GD (1995) Choice of STATs and other substrates specified by modular tyrosine-based motifs in cytokine receptors. Science 267:1349?1353","journal-title":"Science"},{"key":"CR72","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nature01850","volume":"424","author":"Takaoka","year":"2003","unstructured":"Takaoka A, Hayakawa S, Yanai H, Stoiber D, Negishi H, Kikuchi H, Sasaki S, Imai K, Shibue T, Honda K, Taniguchi T (2003) Integration of interferon-alpha\/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424:516?523","journal-title":"Nature"},{"key":"CR75","doi-asserted-by":"crossref","first-page":"3195","DOI":"10.1182\/blood.V96.9.3195","volume":"96","author":"Thiesing","year":"2000","unstructured":"Thiesing JT, Ohno-Jones S, Kolibaba KS, Druker BJ (2000) Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 96:3195?3199","journal-title":"Blood"},{"key":"CR76","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1074\/jbc.M109671200","volume":"277","author":"Uddin","year":"2002","unstructured":"Uddin S, Sassano A, Deb DK, Verma A, Majchrzak B, Rahman A, Malik AB, Fish EN, Platanias LC (2002) Protein kinase C-delta (PKC-delta) is activated by type I interferons and mediates phosphorylation of Stat1 on serine 727. J Biol Chem 277:14408?14416","journal-title":"J Biol Chem"},{"key":"CR77","first-page":"983","volume":"85","author":"Vitale","year":"2000","unstructured":"Vitale G, Tagliaferri P, Caraglia M, Rampone E, Ciccarelli A, Bianco AR, Abbruzzese A, Lupoli G (2000) Slow release lanreotide in combination with interferon-alpha2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 85:983?988","journal-title":"J Clin Endocrinol Metab"},{"key":"CR78","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1002\/1097-0142(20010501)91:9<1797::AID-CNCR1199>3.0.CO;2-P","volume":"91","author":"Vitale","year":"2001","unstructured":"Vitale G, Caraglia M, Ciccarelli A, Lupoli G, Abbruzzese A, Tagliaferri P, Lupoli G (2001) Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1797?1808","journal-title":"Cancer"},{"key":"CR79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1634\/theoncologist.2-4-254","volume":"2","author":"Wadler","year":"1997","unstructured":"Wadler S, Schwartz EL (1997) New advances in interferon therapy of cancer. Oncologist 2:254","journal-title":"Oncologist"},{"key":"CR80","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1002\/(SICI)1097-0142(19970415)79:8<1574::AID-CNCR20>3.0.CO;2-U","volume":"79","author":"Wadler","year":"1997","unstructured":"Wadler S, Schwartz EL, Haynes H, Rameau R, Quish A, Mandeli J, Gallagher R, Hallam S, Fields A, Goldberg G, McGill F, Jennings S, Wallach RC, Runowicz CD (1997) All-trans retinoic acid and interferon-alpha-2a in patients with metastatic or recurrent carcinoma of the uterine cervix: clinical and pharmacokinetic studies. New York Gynecologic Oncology Group. Cancer 79:1574?1580","journal-title":"Cancer"},{"key":"CR81","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1074\/jbc.M108928200","volume":"277","author":"Wagner","year":"2002","unstructured":"Wagner TC, Velichko S, Vogel D, ani MR, Leung S, Ransohoff RM, Stark GR, Perez HD, Croze E (2002) Interferon signaling is dependent on specific tyrosines located within the intracellular domain of IFNAR2c. J Biol Chem 277:1493?1499","journal-title":"J Biol Chem"},{"key":"CR82","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1368-7646(03)00062-1","volume":"6","author":"Weisberg","year":"2003","unstructured":"Weisberg E, Griffin JD (2003) Resistance to imatinib (Glivec): update on clinical mechanisms. Drug Resist Updat 6:231?238","journal-title":"Drug Resist Updat"},{"key":"CR83","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2165\/00003088-199019050-00003","volume":"19","author":"Wills","year":"1990","unstructured":"Wills RJ (1990) Clinical pharmacokinetics of interferons. Clin Pharmacokinet 19:390?399","journal-title":"Clin Pharmacokinet"},{"key":"CR85","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1002\/j.1460-2075.1996.tb00444.x","volume":"15","author":"Yan","year":"1996","unstructured":"Yan H, Krishman H, Greenlund AC, Gupta S, Lim J, Schreiber RD, Schlinder CW, Krolewski JJ (1996) STAT3 activation by type I interferons is dependent on specific tyrosines located in the cytoplasmic domain of interferon receptor chain 2c. EMBO J 15:1064?1074","journal-title":"EMBO J"},{"key":"CR86","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1128\/MCB.16.5.2074","volume":"16","author":"Yan","year":"1996","unstructured":"Yan H, Krishnan K, Lim JT, Contillo LG, Krolewski JJ (1996) Molecular characterization of an alpha interferon receptor 1 subunit (IFNAR1) domain required for TYK2 binding and signal transduction. Mol Cell Biol 16:2074?2082","journal-title":"Mol Cell Biol"},{"key":"CR87","doi-asserted-by":"crossref","first-page":"11711","DOI":"10.1074\/jbc.270.20.11711","volume":"270","author":"Yang","year":"1995","unstructured":"Yang B, Jung D, Motto D, Meyer J, Koretzky G, Campbell KP (1995) SH3 Domain-mediated interaction of dystroglycan and Grb2. J Biol Chem 270:11711?11714","journal-title":"J Biol Chem"},{"key":"CR19","doi-asserted-by":"crossref","first-page":"5568","DOI":"10.1073\/pnas.95.10.5568","volume":"95","author":"Yang","year":"1998","unstructured":"Yang C-H, Murti A, Lawrence MP (1998) STAT3 complements defects in an interferon-resistant cell line: evidence for an essential role for STAT3 in interferon signaling and biological activities. Proc Nat Acad Sci U S A 95:5568?5572","journal-title":"Proc Nat Acad Sci U S A"},{"key":"CR20","doi-asserted-by":"crossref","first-page":"13756","DOI":"10.1074\/jbc.M011006200","volume":"276","author":"Chuan-He","year":"2001","unstructured":"Yang C-H, Murti A, Pfeffer SR, Kim JG, Donner DB, Pfeffer LM (2001) Interferon promotes cell survival by activating nuclear factor?\/? through phosphatidylinositol 3-kinase and Akt. J Biol Chem 276:13756?13761","journal-title":"J Biol Chem"},{"key":"CR88","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1586\/14737140.3.3.295","volume":"3","author":"Yee","year":"2003","unstructured":"Yee KW, Keating A (2003) Advances in targeted therapy for chronic myeloid leukemia. Expert Rev Anticancer Ther 3:295?310","journal-title":"Expert Rev Anticancer Ther"},{"key":"CR89","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1128\/MCB.19.3.2416","volume":"19","author":"You","year":"1999","unstructured":"You M, Yu DH, Feng GS (1999) Shp-2 tyrosine phosphatase functions as a negative regulator of the interferon-stimulated Jak\/STAT pathway. Mol Cell Biol 19:2416?2424","journal-title":"Mol Cell Biol"},{"key":"CR91","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.4049\/jimmunol.163.6.3169","volume":"163","author":"Zella","year":"1999","unstructured":"Zella D, Barabitskaja O, Casareto L, Romerio F, Secchiero P, Reitz MS Jr, Gallo RC, Weichold FF (1999) Recombinant IFN-alpha (2b) increases the expression of apoptosis receptor CD95 and chemokine receptors CCR1 and CCR3 in monocytoid cells. J Immunol 163:3169?3175","journal-title":"J Immunol"},{"key":"CR90","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1006\/bbrc.1994.1479","volume":"200","author":"Zhang","year":"1994","unstructured":"Zhang K, Kumar R (1994) Interferon-alpha inhibits cyclin E- and cyclin D1-dependent CDK-2 kinase activity associated with RB protein and E2F in Daudi cells. Biochem Biophys Res Commun 200:522?528","journal-title":"Biochem Biophys Res Commun"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-004-0549-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-004-0549-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-004-0549-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T20:23:03Z","timestamp":1682713383000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-004-0549-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,6,8]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,1]]}},"alternative-id":["549"],"URL":"https:\/\/doi.org\/10.1007\/s00262-004-0549-1","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,6,8]]}}}